Drug intelligence / Profile preview

multivalent BNT162b2

Development stage: Approved
Lead developer: BioNTech
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Multivalent BNT162b2 is an RNA-based vaccine developed by BioNTech SE. It is designed as a booster injection to provide immunity against SARS-CoV-2, specifically targeting the B.1.1.7 and B.1.617.2 variants. The vaccine works by delivering messenger RNA (mRNA) that instructs human cells to produce the viral spike protein, thereby eliciting an immune response.

Brand names: Comirnaty
Other names: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on multivalent BNT162b2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on multivalent BNT162b2.

Explore the full profile